MDHealthcare · Medical Care Facilities

MD Stock Forecast: Pediatrix Medical Group, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$27

+0.91% on the day

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. hold a median 12-month price target of $28 — +3.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap

$2.2B

Ticker Nerd rank

99 / 100

Median analyst target

$28

Analysts covering

Total return, dividends reinvested

−1.7%

+10.4%

YTD

+24.4%

+71.2%

From 52W high

−2.8%

From 52W low

+71.2%

$16

$27

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pediatrix Medical Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026

99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Momentum

Issuance

Quality

Revisions

Volatility

Accruals

Growth

Size

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (56): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts

2 Buy5 Hold0 Sell

Low $21Median $28High $28

The green dot is the last close — the median target sits +3.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
6 Aug 2026	UBS	Maintains	Neutral	$25 → $28
14 July 2026	Truist Securities	Maintains	Hold	$23 → $28
14 July 2026	Truist Securities	Maintains	Hold	—
12 May 2026	UBS	Maintains	Neutral	—
13 Apr 2026	Truist Securities	Maintains	Hold	—
24 Feb 2026	UBS	Maintains	Neutral	—
20 Feb 2026	Truist Securities	Maintains	Hold	—
10 Nov 2025	Truist Securities	Maintains	Hold	—
5 Nov 2025	UBS	Maintains	Neutral	—
5 Sept 2025	Leerink Partners	Maintains	Market Perform	—
14 Aug 2025	UBS	Maintains	Neutral	—
12 May 2025	UBS	Maintains	Neutral	—
8 May 2025	Macquarie	Maintains	Outperform	—
11 Apr 2025	Truist Securities	Maintains	Hold	—
21 Feb 2025	Truist Securities	Maintains	Hold	—
21 Feb 2025	UBS	Maintains	Neutral	—
6 Jan 2025	Truist Securities	Maintains	Hold	—
16 Dec 2024	Macquarie	Initiates	Outperform	—
19 Nov 2024	Mizuho	Maintains	Neutral	—
5 Nov 2024	Jefferies	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MD appears on the weeks it earns a place.

Estimates

MD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

+2.6%

Analysts raising

Analysts cutting

Fundamentals

Pediatrix Medical Group, Inc. (MD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 12.7×
Price / sales: 1.1×
Price / book: 2.4×
EV / EBITDA: 8.8×

Growth & margins

Revenue growth (YoY): 4.0%
Earnings growth (YoY): 1.5%
Gross margin: 27.2%
Operating margin: 13.4%
Net margin: 9.0%

Returns & dividend

Return on equity: 20.4%
Return on assets: 7.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities

Company	Market cap	TKN rank
MDPediatrix Medical Group, Inc.	$2.2B	99
ADUSAddus HomeCare Corp.	$2.2B	95
SGRYSurgery Partners, Inc.	$2.0B	46
GRDNGuardian Pharmacy Services, Inc.	$2.4B	80
AVAHAveanna Healthcare Holdings, Inc.	$2.5B	90
ASTHAstrana Health, Inc.	$1.9B	67
SNDASonida Senior Living, Inc.	$1.9B	28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pediatrix Medical Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MD news & analysis

Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research published an article titled "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio," highlighting that stronger cash collections, a favorable payer mix, acquisitions, and its telehybrid care model support the company's growth prospects.

Why it matters — MD watchers would care because the report points to operational and strategic strengths, including cash collections, payer mix, acquisitions, and telehybrid care, as factors supporting Pediatrix's growth outlook.

Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research published an article titled "Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock," which promotes the use of the Zacks Style Scores to identify strong, market-beating stocks. The piece highlights Pediatrix Medical Group as such a growth stock.

Why it matters — This item suggests that Zacks' analysis identifies Pediatrix Medical Group as a strong growth stock, which is relevant to investors tracking the company's positioning.

Pediatrix Medical Tops Q2 Earnings on Better Cash Collections

Zacks Investment Research · 6 Aug 2026positive

Pediatrix Medical Group (MD) reported a Q2 earnings beat. Results were lifted by stronger cash collections and a favorable payor mix, even though patient volumes were lower.

Why it matters — The Q2 earnings beat shows that improved cash collections and payor mix helped offset weaker volumes, which matters to those tracking MD's financial performance.

Pediatrix Medical Group Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Pediatrix Medical Group reported Q2 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA guidance of $280–300 million. Stronger revenue-cycle-management collections, payer mix, and patient acuity helped offset lower patient-service volumes.

Why it matters — MD watchers would note the company is holding its full-year profit outlook despite declining patient volumes, suggesting operational and revenue initiatives are effectively supporting margins.

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Pediatrix Medical Group, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational performance for the second quarter of the 2026 fiscal year.

Why it matters — Earnings call transcripts provide investors and analysts with detailed insight into the company's recent financial performance, strategic direction, and management's perspective on operations.

FAQ

Frequently asked questions about MD stock

What is the MD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. have a median 12-month price target of $28, with estimates ranging from $21 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MD stock a buy right now?

Of the 7 analysts covering Pediatrix Medical Group, Inc., 2 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MD?

As at 13 Aug 2026, Pediatrix Medical Group, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will MD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +3.3% from the last close, and Ticker Nerd's factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MD stock forecast for 2030?

No analyst covering Pediatrix Medical Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $28 over the next 12 months.

How has MD stock performed over the past year?

Pediatrix Medical Group, Inc. returned +71.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pediatrix Medical Group, Inc. do?

What is the latest news on MD?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio". Zacks Investment Research published an article titled "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio," highlighting that stronger cash collections, a favorable payer mix, acquisitions, and its telehybrid care model support the company's growth prospects.

Company

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc. operates as a leading provider of physician services within the broader healthcare sector, focusing specifically on neonatal, maternal-fetal, pediatric cardiology, and other related areas. The primary purpose of Pediatrix Medical Group is to ensure specialized and high-quality healthcare for women and children, prioritizing the critical care aspects that are often underserved. Notable for their comprehensive service offerings, Pediatrix plays an essential role in hospital-based management, offering an array of services including clinical staffing, administrative support, and healthcare management solutions. The company's impact on the healthcare industry is significant, as it supports both hospitals and clinics across the United States in delivering superior patient care. As a specialized provider, Pediatrix Medical Group holds a crucial position in addressing the healthcare needs of vulnerable populations, contributing to improved outcomes in neonatal and pediatric care sectors. This strengthens their market significance as they help meet the growing demand for specialized medical services in a dynamic healthcare environment.

CEO Mr. Mark S. Ordan · 4,280 employees · United States · https://www.pediatrix.com